APO Research
Talk to an analyst

APO RESEARCH · REPORT

Group A and C Meningococcal Polysaccharide Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Group A and C Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025192 pages

Choose your research edition.

Industry ResearchGroup A and C Meningococcal Polysaccharide Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Group A and C Meningococcal Polysaccharide Vaccine Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Group A and C Meningococcal Polysaccharide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Group A and C Meningococcal Polysaccharide Vaccine Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Group A and C Meningococcal Polysaccharide Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Group A and C Meningococcal Polysaccharide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Group A and C Meningococcal Polysaccharide Vaccine include Pfizer, Sanofi Pasteur, AIM Bio, Chengda Biotechnology, GlaxoSmithKline, Cansino Biologics, Sinovac, Lanzhou Institute of Biological Products and Royal (Wuxi) Bio-Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Group A and C Meningococcal Polysaccharide Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Group A and C Meningococcal Polysaccharide Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Group A and C Meningococcal Polysaccharide Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Group A and C Meningococcal Polysaccharide Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Group A and C Meningococcal Polysaccharide Vaccine Segment by Company

Pfizer

Sanofi Pasteur

AIM Bio

Chengda Biotechnology

GlaxoSmithKline

Cansino Biologics

Sinovac

Lanzhou Institute of Biological Products

Royal (Wuxi) Bio-Pharmaceutical

Merck & Co.

Toyouvax

Walvax

Zhifei Biological

Group A and C Meningococcal Polysaccharide Vaccine Segment by Type

Polysaccharide-protein Conjugate Vaccine

Polysaccharide Vaccine

Group A and C Meningococcal Polysaccharide Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Group A and C Meningococcal Polysaccharide Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Group A and C Meningococcal Polysaccharide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Group A and C Meningococcal Polysaccharide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Group A and C Meningococcal Polysaccharide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Group A and C Meningococcal Polysaccharide Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Group A and C Meningococcal Polysaccharide Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Group A and C Meningococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Group A and C Meningococcal Polysaccharide Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Group A and C Meningococcal Polysaccharide Vaccine Industry Trends Table 2. Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers Table 3. Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges Table 4. Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints Table 5. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Manufacturers (Units) & (2021-2026) Table 8. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Manufacturers Table 9. Global Group A and C Meningococcal Polysaccharide Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Group A and C Meningococcal Polysaccharide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Group A and C Meningococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers, Product Type & Application Table 13. Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Group A and C Meningococcal Polysaccharide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Polysaccharide-protein Conjugate Vaccine Table 17. Major Manufacturers of Polysaccharide Vaccine Table 18. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type 2021 VS 2025 VS 2032 (Units) Table 19. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2026) & (Units) Table 20. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2027-2032) & (Units) Table 21. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type 2021 VS 2025 VS 2032 (Units) Table 24. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2026) & (Units) Table 25. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2027-2032) & (Units) Table 26. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Centers for Disease Control and Prevention Table 30. Major Manufacturers of Others Table 31. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application 2021 VS 2025 VS 2032 (Units) Table 32. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2026) & (Units) Table 33. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2027-2032) & (Units) Table 34. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2026) Table 35. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2027-2032) Table 36. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application 2021 VS 2025 VS 2032 (Units) Table 37. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2026) & (Units) Table 38. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2027-2032) & (Units) Table 39. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2026) Table 40. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2027-2032) Table 41. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 42. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026) & (Units) Table 43. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Forecasted by Region (2027-2032) & (Units) Table 45. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 47. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 48. North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 49. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 50. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 51. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 52. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 53. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 54. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 55. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Units) Table 56. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2026) & (Units) Table 57. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2027-2032) & (Units) Table 58. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2026) Table 62. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2027-2032) Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 67. Pfizer Recent Development Table 68. Sanofi Pasteur Company Information Table 69. Sanofi Pasteur Business Overview Table 70. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 72. Sanofi Pasteur Recent Development Table 73. AIM Bio Company Information Table 74. AIM Bio Business Overview Table 75. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 77. AIM Bio Recent Development Table 78. Chengda Biotechnology Company Information Table 79. Chengda Biotechnology Business Overview Table 80. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 82. Chengda Biotechnology Recent Development Table 83. GlaxoSmithKline Company Information Table 84. GlaxoSmithKline Business Overview Table 85. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 87. GlaxoSmithKline Recent Development Table 88. Cansino Biologics Company Information Table 89. Cansino Biologics Business Overview Table 90. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 92. Cansino Biologics Recent Development Table 93. Sinovac Company Information Table 94. Sinovac Business Overview Table 95. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 97. Sinovac Recent Development Table 98. Lanzhou Institute of Biological Products Company Information Table 99. Lanzhou Institute of Biological Products Business Overview Table 100. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 102. Lanzhou Institute of Biological Products Recent Development Table 103. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 104. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 105. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 107. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 108. Merck & Co. Company Information Table 109. Merck & Co. Business Overview Table 110. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 112. Merck & Co. Recent Development Table 113. Toyouvax Company Information Table 114. Toyouvax Business Overview Table 115. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 117. Toyouvax Recent Development Table 118. Walvax Company Information Table 119. Walvax Business Overview Table 120. Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 122. Walvax Recent Development Table 123. Zhifei Biological Company Information Table 124. Zhifei Biological Business Overview Table 125. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales (Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio Table 127. Zhifei Biological Recent Development Table 128. Key Raw Materials Table 129. Raw Materials Key Suppliers Table 130. Group A and C Meningococcal Polysaccharide Vaccine Distributors List Table 131. Group A and C Meningococcal Polysaccharide Vaccine Customers List Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Group A and C Meningococcal Polysaccharide Vaccine Product Image Figure 2. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Group A and C Meningococcal Polysaccharide Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Group A and C Meningococcal Polysaccharide Vaccine Sales (2021-2032) & (Units) Figure 5. Global Group A and C Meningococcal Polysaccharide Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Group A and C Meningococcal Polysaccharide Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Polysaccharide-protein Conjugate Vaccine Image Figure 9. Polysaccharide Vaccine Image Figure 10. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032) & (Units) Figure 11. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (Units) Figure 14. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Centers for Disease Control and Prevention Image Figure 18. Others Image Figure 19. Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032) & (Units) Figure 20. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032) Figure 22. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (Units) Figure 23. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032) Figure 25. North America Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 26. North America Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 27. U.S. Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 28. Canada Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 29. Mexico Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 30. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 31. Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 32. Germany Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 33. France Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 34. U.K. Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 35. Italy Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 36. Netherlands Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 37. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 38. Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 39. China Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 40. Japan Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 41. South Korea Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 42. Southeast Asia Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 43. India Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 44. Australia Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 45. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 46. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Country (2021-2032) Figure 47. Brazil Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 48. South Africa Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 49. Saudi Arabia Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 50. Turkey Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 51. Argentina Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 52. UAE Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 53. Egypt Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 54. Chile Group A and C Meningococcal Polysaccharide Vaccine Sales and Growth Rate (2021-2032) & (Units) Figure 55. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 58. North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Group A and C Meningococcal Polysaccharide Vaccine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Group A and C Meningococcal Polysaccharide Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Polysaccharide-protein Conjugate Vaccine
  • Polysaccharide Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • Pfizer
  • Sanofi Pasteur
  • AIM Bio
  • Chengda Biotechnology
  • GlaxoSmithKline
  • Cansino Biologics
  • Sinovac
  • Lanzhou Institute of Biological Products
  • Royal (Wuxi) Bio-Pharmaceutical
  • Merck & Co.
  • Toyouvax
  • Walvax
  • Zhifei Biological

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Group A and C Meningococcal Polysaccharide Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Group A and C Meningococcal Polysaccharide Vaccine Market Dynamics
  1. 2.1 Group A and C Meningococcal Polysaccharide Vaccine Industry Trends
  2. 2.2 Group A and C Meningococcal Polysaccharide Vaccine Industry Drivers
  3. 2.3 Group A and C Meningococcal Polysaccharide Vaccine Industry Opportunities and Challenges
  4. 2.4 Group A and C Meningococcal Polysaccharide Vaccine Industry Restraints
3 Group A and C Meningococcal Polysaccharide Vaccine Market by Manufacturers
  1. 3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Group A and C Meningococcal Polysaccharide Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Group A and C Meningococcal Polysaccharide Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Group A and C Meningococcal Polysaccharide Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Group A and C Meningococcal Polysaccharide Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Group A and C Meningococcal Polysaccharide Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Group A and C Meningococcal Polysaccharide Vaccine Tier 1, Tier 2, and Tier 3
4 Group A and C Meningococcal Polysaccharide Vaccine Market by Type
  1. 4.1 Group A and C Meningococcal Polysaccharide Vaccine Type Introduction
  2. 4.1.1 Polysaccharide-protein Conjugate Vaccine
  3. 4.1.2 Polysaccharide Vaccine
  4. 4.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type
  5. 4.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type
  9. 4.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Type (2021-2032)
5 Group A and C Meningococcal Polysaccharide Vaccine Market by Application
  1. 5.1 Group A and C Meningococcal Polysaccharide Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application
  6. 5.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application
  10. 5.3.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Application (2021-2032)
6 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region
  1. 6.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Group A and C Meningococcal Polysaccharide Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Group A and C Meningococcal Polysaccharide Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region
  1. 7.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region
  2. 7.1.1 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Group A and C Meningococcal Polysaccharide Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Group A and C Meningococcal Polysaccharide Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 Sanofi Pasteur
  8. 8.2.1 Sanofi Pasteur Company Information
  9. 8.2.2 Sanofi Pasteur Business Overview
  10. 8.2.3 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Pasteur Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  12. 8.2.5 Sanofi Pasteur Recent Developments
  13. 8.3 AIM Bio
  14. 8.3.1 AIM Bio Company Information
  15. 8.3.2 AIM Bio Business Overview
  16. 8.3.3 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AIM Bio Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  18. 8.3.5 AIM Bio Recent Developments
  19. 8.4 Chengda Biotechnology
  20. 8.4.1 Chengda Biotechnology Company Information
  21. 8.4.2 Chengda Biotechnology Business Overview
  22. 8.4.3 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chengda Biotechnology Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  24. 8.4.5 Chengda Biotechnology Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Cansino Biologics
  32. 8.6.1 Cansino Biologics Company Information
  33. 8.6.2 Cansino Biologics Business Overview
  34. 8.6.3 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cansino Biologics Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  36. 8.6.5 Cansino Biologics Recent Developments
  37. 8.7 Sinovac
  38. 8.7.1 Sinovac Company Information
  39. 8.7.2 Sinovac Business Overview
  40. 8.7.3 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sinovac Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  42. 8.7.5 Sinovac Recent Developments
  43. 8.8 Lanzhou Institute of Biological Products
  44. 8.8.1 Lanzhou Institute of Biological Products Company Information
  45. 8.8.2 Lanzhou Institute of Biological Products Business Overview
  46. 8.8.3 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lanzhou Institute of Biological Products Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  48. 8.8.5 Lanzhou Institute of Biological Products Recent Developments
  49. 8.9 Royal (Wuxi) Bio-Pharmaceutical
  50. 8.9.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  51. 8.9.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  52. 8.9.3 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Royal (Wuxi) Bio-Pharmaceutical Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  54. 8.9.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  55. 8.10 Merck & Co.
  56. 8.10.1 Merck & Co. Company Information
  57. 8.10.2 Merck & Co. Business Overview
  58. 8.10.3 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co. Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  60. 8.10.5 Merck & Co. Recent Developments
  61. 8.11 Toyouvax
  62. 8.11.1 Toyouvax Company Information
  63. 8.11.2 Toyouvax Business Overview
  64. 8.11.3 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Toyouvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  66. 8.11.5 Toyouvax Recent Developments
  67. 8.12 Walvax
  68. 8.12.1 Walvax Company Information
  69. 8.12.2 Walvax Business Overview
  70. 8.12.3 Walvax Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Walvax Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  72. 8.12.5 Walvax Recent Developments
  73. 8.13 Zhifei Biological
  74. 8.13.1 Zhifei Biological Company Information
  75. 8.13.2 Zhifei Biological Business Overview
  76. 8.13.3 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Zhifei Biological Group A and C Meningococcal Polysaccharide Vaccine Product Portfolio
  78. 8.13.5 Zhifei Biological Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Group A and C Meningococcal Polysaccharide Vaccine Value Chain Analysis
  2. 9.1.1 Group A and C Meningococcal Polysaccharide Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Group A and C Meningococcal Polysaccharide Vaccine Production Mode & Process
  6. 9.2 Group A and C Meningococcal Polysaccharide Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Group A and C Meningococcal Polysaccharide Vaccine Distributors
  9. 9.2.3 Group A and C Meningococcal Polysaccharide Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst